Anti-Human DKK1 Recombinant Antibody (BHQ880) (CAT#: TAB-214CL)

Recombinant Human monoclonal antibody expressed in CHO binding to Human DKK1. BHQ880 is a human neutralizing IgG1 anti-DKK1 monoclonal antibody, that is being investigated for its impact on multiple myeloma-related bone disease and as an agent with potential anti-myeloma activity. BHQ880 in combination with zoledronic acid and anti-myeloma therapy was well tolerated and demonstrated potential clinical activity in patients with relapsed or refractory multiple myeloma.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
IHC

Figure 1 BHQ880 reverses the inhibitory effect of MM cells on osteoblastogenesis.

Figure 1 BHQ880 reverses the inhibitory effect of MM cells on osteoblastogenesis.

BMSC obtained from BM aspirate of MM patients were stimulated with OB differentiation media for 3 weeks in the presence of IgG1 isotype control antibody or 1 μg/mL BHQ880 and in the absence of INA-6 MM cells. At the end of the culture period, the cells were fixed in 10% formaldehyde and stained with Alizarin Red for 30 minutes.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

ELISA

Figure 2 BHQ880 reverses the inhibitory effect of MM cells on osteoblastogenesis.

Figure 2 BHQ880 reverses the inhibitory effect of MM cells on osteoblastogenesis.

Supernatants from these assays were analyzed for huIL-6 level by ELISA. IL-6 production was suppressed after treatment with BHQ880 in supernatants from both cultures with and without MM cells.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

IB

Figure 3 BHQ880 inhibits IL-6 production and MM cell adhesion and modulates β-catenin and NF-κB pathways in BMSC from MM patients.

Figure 3 BHQ880 inhibits IL-6 production and MM cell adhesion and modulates β-catenin and NF-κB pathways in BMSC from MM patients.

Cytoplasmic fraction was subjected to immunoblotting using anti-phospho β-catenin antibody and anti–β-catenin antibody.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.

IHC

Figure 4 BHQ880 improves bone disease in a murine model of human MM.

Figure 4 BHQ880 improves bone disease in a murine model of human MM.

One month after treatment, bone chips were retrieved and decalcified, and sections from BHQ880-treated bones were immunohistochemically stained for ALP. Sections were observed and photographed with a Nikon transmitted light microscope. Original magnification ×200.

Fulciniti, M., Tassone, P., Hideshima, T., Vallet, S., Nanjappa, P., Ettenberg, S. A., ... & Mitsiades, C. (2009). Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood, 114(2), 371-379.


Specifications

  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • Antibody
  • Species Reactivity
  • Human
  • Applications
  • IHC, ELISA, IB
  • Related Disease
  • Bone-related Diseases; Multiple Myeloma

Product Property

  • Purity
  • >95%, by SDS-PAGE, under reducing conditions
  • Storage
  • ≥1 year at -20°C. If the reconstituted antibody cannot be used within two weeks, it should be aliquoted into smaller vials and stored at -20°C

Applications

  • Application Notes
  • This antibody has been reported for use in Immunohistochemistry, Enzyme-Linked Immunosorbent Assay and Immunoblot.

Target

  • Alternative Names
  • DKK1; dickkopf WNT signaling pathway inhibitor 1; SK; DKK-1; dickkopf-related protein 1; hDkk-1; dickkopf-1 like; dickkopf 1 homolog; dickkopf-like protein 1; dickkopf related protein-1

Related Resources

  • Related Signaling Pathways

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "DKK1"

Recombinant Antibody

Neutralizing Antibody

CAT Product Name Application Type
NEUT-703CQ Rabbit Anti-DKK1 Recombinant Antibody (clone CBL1003) Neut Rabbit IgG

Rabbit Monoclonal Antibody

Submit a review or a question
There are currently no Customer reviews or questions for TAB-214CL. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare